# BCRX catalysts: BIOCRYST PHARMACEUTICALS INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/bcrx/catalysts

> BIOCRYST PHARMACEUTICALS INC (BCRX) has 2 upcoming catalysts. The next is the navenibart topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for BCRX?

BIOCRYST PHARMACEUTICALS INC (BCRX) has 2 upcoming catalysts. The next is the navenibart topline data readout, early 2027. Press release filed with the SEC (EX-99): "Navenibart is in Phase 3 clinical development with top line data from the pivotal ALPHA-ORBIT trial expected in early 2027 and has the potential to be the leading injectable HAE treatment." [Calendar and source filings](https://sec-api.dev/companies/bcrx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001140361-25-038031, https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex99-2.htm (retrieved 2026-11-12). Last confirmed 2025-10-14. Cite: https://sec-api.dev/companies/bcrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | BIOCRYST PHARMACEUTICALS INC |
| Ticker | BCRX (Nasdaq) |
| SEC CIK | 882796 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/bcrx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 3, 2020 | [ORLADEYO® (berotralstat) FDA approval](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | completed, approved | "NDA214094 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20201203, review_priority STANDARD; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214094%22)) |
| January 28, 2021 | [Rapivab (peramivir) label expansion decision](https://sec-api.dev/pdufa/peramivir) | BCRX |  | completed, approved | "NDA206426 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210128, review_priority PRIORITY; sponsor_name BIOCRYST; product RAPIVAB (PERAMIVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206426%22)) |
| 2025 | [ORLADEYO® (berotralstat) NDA/BLA submission](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | scheduled | "The company is on track to submit a new drug application (NDA) in 2025 to the U.S. Food and Drug Administration (FDA) to expand the ORLADEYO label to children with HAE aged 2 to 11 using an oral granule formulation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm)) |
| 2025 | [Syndrome interim data readout](https://sec-api.dev/pdufa/syndrome) | BCRX | Netherton syndrome, into clinical trials | scheduled | "The company has advanced BCX17725, its KLK5 inhibitor for the treatment of Netherton syndrome, into clinical trials and expects initial data from the program in 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm)) |
| February 24, 2025 | [ORLADEYO® (berotralstat) interim data readout](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 | completed, positive | "Earlier today, the company announced positive results from an interim analysis of the ongoing APeX-P clinical trial evaluating ORLADEYO in children with HAE aged 2 to 11." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm)) |
| February 24, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325001020/exh_991.htm)) |
| May 5, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325002739/exh_991.htm)) |
| June 23, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 years due | scheduled | "On June 23, 2025, the FDA extended the PDUFA goal date for our NDA for the use of once-daily ORLADEYO oral granules in pediatric patients with HAE aged 2 to 11 years due to our submission of additional final reports and formulation data, which resulted in a standard three-month extension to the original goal date to provide time for a full review of the submission." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm)) |
| August 4, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325004977/exh_991.htm)) |
| late 2025 | [Avoralstat interim data readout](https://sec-api.dev/pdufa/avoralstat) | BCRX |  | scheduled | "On February 24, 2025, we reaffirmed our expectation to advance avoralstat into a clinical trial of patients with DME in 2025 and announced that initial clinical data from the avoralstat program is targeted by the end of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025022658/bcrx-20250331.htm)) |
| September 12, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | scheduled | "The FDA also granted priority review of the application, with a Prescription Drug User Fee Act ("PDUFA") target action date of September 12, 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/882796/000117184325003152/f8k_051425.htm)) |
| November 3, 2025 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm)) |
| December 11, 2025 | [ORLADEYO® (berotralstat) FDA approval](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to <12 years | completed, approved | "NDA219776 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20251211, review_priority PRIORITY; sponsor_name BIOCRYST; product ORLADEYO (BEROTRALSTAT DIHYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219776%22)) |
| December 12, 2025 | [BIOCRYST PHARMACEUTICALS INC PDUFA date](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | scheduled | "The new PDUFA target action date for our NDA is December 12, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025037795/bcrx-20250630.htm)) |
| December 12, 2025 | [ORLADEYO® (berotralstat) PDUFA date](https://sec-api.dev/pdufa/berotralstat) | BCRX | HAE aged 2 to 11 | completed, approved | "The Prescription Drug User Fee Act goal date for the company's new drug application for ORLADEYO granules in children with HAE aged 2 to <12 is December 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184325006881/exh_991.htm)) |
| Q1 2026 | [Syndrome interim data readout](https://sec-api.dev/pdufa/syndrome) | BCRX |  | scheduled | "On November 3, 2025, we announced that we expect initial data from Netherton syndrome patients participating in our phase 1 trial of BCX17725 by the end of the first quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828025048785/bcrx-20250930.htm)) |
| January 12, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "The actual amount of stock-based compensation, restructuring and transaction-related costs for the full year 2026 could have a material impact on GAAP reported results for the guidance period." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/exh_991.htm)) |
| February 26, 2026 | [Navenibart interim data readout](https://sec-api.dev/pdufa/navenibart) | BCRX |  | completed, positive | "On February 26, 2026, we announced that new positive, interim results from the long-term, open-label ALPHA-SOLAR trial show sustained, robust HAE attack suppression with navenibart administered every three and six months." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026031238/bcrx-20260331.htm)) |
| February 26, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/exh_991.htm)) |
| May 6, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326003052/exh_991.htm)) |
| August 5, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326005223/exh_991.htm)) |
| late 2026 | [Syndrome interim data readout](https://sec-api.dev/pdufa/syndrome) | BCRX |  | scheduled | "The company has enrolled Part 4 of this trial and expects to report initial data in patients with NS by the end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)) |
| October 21, 2026 | [ORLADEYO® (berotralstat) label expansion decision](https://sec-api.dev/pdufa/berotralstat) | BCRX |  | completed, approved | "On October 21, 2026, we announced that the FDA approved the supplemental new drug application for use of the 150 mg oral pellet formulation of once-daily ORLADEYO for prophylactic therapy in adults and adolescents aged 12 years and older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/882796/000162828026070112/bcrx-20260930.htm)) |
| November 4, 2026 | [BIOCRYST PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/bcrx/catalysts) | BCRX |  | completed | "BioCryst Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)) |
| early 2027 | [Navenibart topline data readout](https://sec-api.dev/pdufa/navenibart) | BCRX |  | scheduled | "Navenibart is in Phase 3 clinical development with top line data from the pivotal ALPHA-ORBIT trial expected in early 2027 and has the potential to be the leading injectable HAE treatment." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000114036125038031/ef20057029_ex99-2.htm)) |
| Q3 2027 | [Navenibart topline data readout](https://sec-api.dev/pdufa/navenibart) | BCRX |  | scheduled | "The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)) |

## Drugs

- [Avoralstat](https://sec-api.dev/pdufa/avoralstat): 
- [ORLADEYO® (berotralstat)](https://sec-api.dev/pdufa/berotralstat): hae aged 2 to <12 years, hae aged 2 to 11, hae aged 2 to <12, hereditary angioedema aged 2 to <12 years, hereditary angioedema, hae aged 2 to 11 years due
- [Navenibart](https://sec-api.dev/pdufa/navenibart): 
- [Rapivab (peramivir)](https://sec-api.dev/pdufa/peramivir): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/bcrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BCRX catalysts: BIOCRYST PHARMACEUTICALS INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/bcrx/catalysts

```bibtex
@misc{secapidev_companies_bcrx_catalysts_20261116,
  title        = {BCRX catalysts: BIOCRYST PHARMACEUTICALS INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/bcrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_bcrx_catalysts_20261116","title":"BCRX catalysts: BIOCRYST PHARMACEUTICALS INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/bcrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
